BioCentury
ARTICLE | Company News

AbbVie, Calibr to develop universal CAR T therapies

June 25, 2018 11:26 AM UTC

AbbVie Inc. (NYSE:ABBV) and the California Institute for Biomedical Research (La Jolla, Calif.) partnered to develop universal CAR T therapies using the non-profit's switchable CAR T technology to treat hematological and solid tumors.

AbbVie will pay Calibr an undisclosed upfront license fee to gain exclusive access to the technology for four years. The partners will share preclinical development responsibilities, and AbbVie will be responsible for clinical development and commercialization...